EyePoint Pharmaceuticals

Press Releases

EyePoint Pharmaceuticals Announces Appointment of Leonard Blum as Executive Vice President and General Manager, U.S.
May 16, 2018
WATERTOWN, Mass. , May 16, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the appointment of Leonard M.
EyePoint Pharmaceuticals Reports Fiscal Third Quarter 2018 Results
May 08, 2018
Completed Substantive Strategic Initiatives to Accelerate Transformation to a Commercial Company Conference Call and Webcast Today, May 8th , at 4:30 p.m. ET WATERTOWN, Mass. , May 08, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ:EYPT), a specialty biopharmaceutical company committed
EyePoint Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
Apr 19, 2018
WATERTOWN, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) (ASX:PVA), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its third quarter of fiscal year 2018 on Tuesday, May 8, 2018.
EyePoint Pharmaceuticals' YUTIQ™ for Posterior Segment Uveitis to be Presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Apr 18, 2018
WATERTOWN, Mass. , April 18, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ:EYPT) (ASX:PVA), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that two abstracts supporting the Company's YUTIQ™ (fluocinolone
EyePoint Pharmaceuticals Strengthens Global IP with Notices of Allowance for Two U.S. Patents Related to DEXYCU™
Apr 12, 2018
WATERTOWN, Mass. , April 12, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) (ASX:PVA), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the U.S.
pSivida Corp. Announces Transformative Acquisition of Icon Bioscience Inc. and Growth Capital Financing with Essex Woodlands Healthcare Partners - Company Will Rebrand as EyePoint Pharmaceuticals, Inc.
Mar 28, 2018
Acquisition and additional funding significantly accelerate the company's transformation to a specialty biopharmaceutical company with the potential to commercialize two ophthalmic products in 1H 2019 Icon Bioscience's DEXYCU ™ (dexamethasone intraocular suspension) 9% was approved by the FDA on
pSivida Announces FDA Acceptance For Filing of New Drug Application (NDA) for Durasert™ Three-Year Treatment for Posterior Segment Uveitis
Mar 19, 2018
WATERTOWN, Mass. , March 19, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that its New Drug Application (NDA) for Durasert three-year treatment for posterior segment uveitis has been
pSivida To Present at the 30th Annual ROTH Conference
Mar 05, 2018
WATERTOWN, Mass. , March 05, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, announced today that Nancy Lurker , President and Chief Executive Officer, is scheduled to present an overview of the Company
pSivida to Present at the 2018 BIO CEO & Investor Conference
Feb 09, 2018
WATERTOWN, Mass. , Feb. 09, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, announced today that Nancy Lurker , President and Chief Executive Officer, is scheduled to present an overview of the Company
pSivida Corp. Reports Second Quarter FY2018 Results; Continues to Achieve Milestones and Timelines
Feb 07, 2018
Newly Released Second Phase 3 Study Data for Durasert Three-Year Treatment for Posterior Segment Uveitis Shows Positive Efficacy and Safety Profile Maintained at 12 Months       Awaiting FDA Decision to Accept NDA Submission for Review Conference Call and Webcast Today, February 7th , at 4:30 p.m.
pSivida's Second Phase 3 Study for Durasert™ Three-year Treatment for Posterior Segment Uveitis Maintains Positive Efficacy and Safety Profile at 12 Months
Feb 07, 2018
Highly Significant Difference Between Durasert and Sham in Prevention of Uveitis Recurrence at 12 Months Fiscal Q2 2018 Results Conference Call Scheduled for Today at 4:30 p.m.ET WATERTOWN, Mass. , Feb. 07, 2018 (GLOBE NEWSWIRE) --  pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development
pSivida Corp. Announces Second Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
Jan 24, 2018
Conference Call Scheduled for 4:30 p.m. ET on Wednesday, February 7th
pSivida Submits New Drug Application (NDA) for Durasert™ Three-Year Treatment for Posterior Segment Uveitis to the U.S. FDA
Jan 08, 2018
Proven Durasert Technology Has to Date Received FDA Approval for Three of the Four Sustained Release Drug Products Approved for Back-of-the-Eye Diseases
pSivida Granted Waiver by the FDA for New Drug Application Filing Fee
Jan 04, 2018
WATERTOWN, Mass. , Jan. 04, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products, today announced that the U.S. Food and Drug Administration (FDA) granted its request for a small business waiver of the Prescription
pSivida to Present at the Annual Biotech Showcase Conference
Jan 02, 2018
WATERTOWN, Mass. , Jan. 02, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products, announced today that Nancy Lurker , President and Chief Executive Officer, will present at the Annual Biotech Showcase conference on
HSS and pSivida Report Positive Phase 1 Knee Osteoarthritis Pain Study Data
Dec 14, 2017
Sustained Release Technology Well Tolerated and Provides Pain Reduction
pSivida Corp. Builds Momentum During First Quarter FY18; Continues Operating Milestone Execution
Nov 07, 2017
NDA Filing for Durasert Three-year Treatment for Posterior Segment Uveitis Remains on Track for Late December 2017/Early January 2018 Conference Call and Webcast Today, November 7th , at 8:30 a.m. ET WATERTOWN, Mass. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- pSivida Corp.
pSivida Corp. Announces First Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
Oct 18, 2017
Conference Call Scheduled for 8:30 a.m. ET on Tuesday, November 7th
pSivida and Nicox Enter Strategic Collaboration Agreement to Develop Sustained Release Drug to Lower Intraocular Pressure in Patients with Glaucoma
Oct 10, 2017
Focus will be on Combining pSivida's Bioerodible Sustained Release Delivery Technology with Nicox's New Nitric Oxide Donating Compounds
pSivida Partners with Global Pharmaceuticals Company to Develop Sustained Release Formulations of Glaucoma Drugs
Sep 26, 2017
WATERTOWN, Mass. , Sept. 26, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, has signed an agreement with a major global pharmaceutical company to develop two glaucoma drugs with pSivida's proprietary
Displaying 1 - 20 of 303
EyePoint Pharmaceuticals